About Us
Company Profile Mission Leadership
Senior Management Board of Directors Scientific Advisory Boards
Milestones Sustainability
Innovation
Discovery Translational Research Process Development Clinical Development Manufacturing
Products
Pipeline Core products
Osemitamab(TST001) TST002 TST003
Scientific Publications
Partnering
Investors
News & Events
Press Release In The News Events
Careers
Life in Transcenta Job Opportunity

TST012

FGFR2b

Target:: FGFR2b

Indication:: Solid Tumors

Project Status:: Preclinical

TST012 is an ADC candidate targeting FGFR2b, targeting biomarker expressing gastric cancer and other solid tumors. We have obtained the lead molecule and finished the cell line development. Such targeted program will be complementary to our Osemitamab (TST001) program in gastric cancer.